Medical device maker Aesculap Implant Systems, LLC is set to pay out a hefty $38.5 million to settle claims under the False Claims Act tied to accusations of selling faulty knee implants. Aesculap, based in Center Valley, Pennsylvania, faced serious allegations that not only did it hawk the VEGA System® Knee System to medical professionals with full knowledge that the product was likely to fail, but it also allegedly sweetened the deal with unlawful perks to a doctor to boost their use—moves that put patient health at direct risk and slapped federal healthcare programs with unwarranted costs, as the Department of Justice reported recently.
In an uncovering that calls into question Aesculap's operational ethics, the United States Attorney David Metcalf brought to light that from July 30, 2010, to June 17, 2023; Aesculap allegedly sold the Vega with a clear awareness of its defectiveness—the bone cement crucial for securing the implant to the knee would not adhere properly, potentially leading to loosening of the device post-surgery, and in turn, pain and the need for corrective procedures, despite this, the company proceeded with sales without alerting healthcare providers of these issues.
The settlement also wraps up accusations of Aesculap’s involvement in illicit payments to an orthopedic surgeon in Georgia, as a form of inducement to use and endorse the Vega Knee System; this included consulting fees, trips, and entertainment, which squarely falls foul of the Anti-Kickback Statute. U.S. Attorney Metcalf conveyed the gravity of the situation, stating, "Doctors who implant medical devices need complete and accurate information about those devices to ensure they choose the best and safest options for their patients," emphasizing the betrayal of trust when companies mislead those at the healthcare's frontline, as noted by the press release.
Extended well beyond a civil agreement, the company's troubles don’t end there, an Aesculap employee has already faced the judicial music, pleading guilty and being sentenced to prison for introducing unauthorized medical devices into the market—namely the ELAN-4 Air Drill and the JS Series SterilContainer S2 that hit shelves without the FDA clearance, forgery by the employee made it appear as though regulatory approval had been secured when truth was otherwise.
With whistleblowers paving the way under the qui tam provisions of the False Claims Act, the involved parties, John Marien, Michael McGee, and Brad Stafford, are due for a share of the recovery. The concerted efforts of the U.S. Attorney’s Office for the Eastern District of Pennsylvania and other federal agencies like the Justice Department’s Civil Division, HHS-OIG, and FDA-OCI, spotlight the U.S. government's unwavering commitment to root out healthcare fraud, signaling the heavy cost of deception and misconduct within the sector.
